Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127572491 | 12757249 | 1 | I | 2006 | 20080929 | 20160919 | 20160919 | PER | US-ASTRAZENECA-2008BM13865 | ASTRAZENECA | 36.00 | YR | F | Y | 99.80000 | KG | 20160919 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127572491 | 12757249 | 1 | PS | BYETTA | EXENATIDE | 1 | Subcutaneous | 21773 | 5 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | |||||||
| 127572491 | 12757249 | 2 | SS | BYETTA | EXENATIDE | 1 | Subcutaneous | A473293 | 21773 | 10 | UG | SOLUTION FOR INJECTION IN PRE-FILLED PEN | BID | ||||||
| 127572491 | 12757249 | 3 | SS | FARXIGA | DAPAGLIFLOZIN PROPANEDIOL | 1 | Oral | 0 | TABLET | ||||||||||
| 127572491 | 12757249 | 4 | C | EXENATIDE | EXENATIDE | 1 | 0 | ||||||||||||
| 127572491 | 12757249 | 5 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | Oral | 0 | 1000 | MG | BID | ||||||||
| 127572491 | 12757249 | 6 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | 0 | 20 | MG | QD | |||||||||
| 127572491 | 12757249 | 7 | C | BENAZEPRIL | BENAZEPRIL HYDROCHLORIDE | 1 | 0 | 10 | MG | QD | |||||||||
| 127572491 | 12757249 | 8 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | 0 | ||||||||||||
| 127572491 | 12757249 | 9 | C | TRICOR | FENOFIBRATE | 1 | 0 | 145 | MG | QD | |||||||||
| 127572491 | 12757249 | 10 | C | YASMIN | DROSPIRENONEETHINYL ESTRADIOL | 1 | EVERY DAY | 0 | |||||||||||
| 127572491 | 12757249 | 11 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | UNK | 0 | |||||||||||
| 127572491 | 12757249 | 12 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | Oral | 0 | 2 | MG | QD | ||||||||
| 127572491 | 12757249 | 13 | C | AVANDIA | ROSIGLITAZONE MALEATE | 1 | Oral | 0 | 4 | MG | QD | ||||||||
| 127572491 | 12757249 | 14 | C | HUMALOG | INSULIN LISPRO | 1 | Subcutaneous | THREE TIMES A DAY | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127572491 | 12757249 | 1 | Type 2 diabetes mellitus |
| 127572491 | 12757249 | 2 | Type 2 diabetes mellitus |
| 127572491 | 12757249 | 5 | Type 2 diabetes mellitus |
| 127572491 | 12757249 | 8 | Oedema |
| 127572491 | 12757249 | 10 | Contraception |
| 127572491 | 12757249 | 13 | Type 2 diabetes mellitus |
| 127572491 | 12757249 | 14 | Type 2 diabetes mellitus |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127572491 | 12757249 | Blood glucose increased | |
| 127572491 | 12757249 | Decreased appetite | |
| 127572491 | 12757249 | Drug dose omission | |
| 127572491 | 12757249 | Glycosylated haemoglobin increased | |
| 127572491 | 12757249 | Limb injury | |
| 127572491 | 12757249 | Oedema | |
| 127572491 | 12757249 | Skin abrasion | |
| 127572491 | 12757249 | Skin discolouration | |
| 127572491 | 12757249 | Weight fluctuation |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127572491 | 12757249 | 1 | 2006 | 2006 | 0 | |
| 127572491 | 12757249 | 2 | 2006 | 0 | ||
| 127572491 | 12757249 | 5 | 2006 | 0 | ||
| 127572491 | 12757249 | 8 | 200710 | 0 | ||
| 127572491 | 12757249 | 11 | 200602 | 0 | ||
| 127572491 | 12757249 | 12 | 200602 | 200710 | 0 | |
| 127572491 | 12757249 | 13 | 200602 | 200710 | 0 | |
| 127572491 | 12757249 | 14 | 2008 | 0 |